Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Quantum Biopharma ( (TSE:QNTM) ) has issued an announcement.
On March 31, 2025, Quantum BioPharma entered into a joint clinical study with Massachusetts General Hospital to validate a novel PET imaging technique for monitoring demyelination in multiple sclerosis patients. This collaboration aims to advance the use of [18F]3F4AP PET scans as a sensitive biomarker for assessing demyelination, potentially enhancing the evaluation of remyelinating and neuroprotective treatments. The study’s findings could significantly impact Quantum BioPharma’s Lucid-MS development program, which targets myelin protection and demyelination prevention.
More about Quantum Biopharma
Quantum BioPharma is a biopharmaceutical company focused on developing innovative biotech solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. The company is advancing its lead compound, Lucid-MS, which has shown promise in preventing and reversing myelin degradation in multiple sclerosis. Quantum BioPharma also has strategic investments and retains a significant ownership stake in Celly Nutrition Corp.
YTD Price Performance: 88.97%
Average Trading Volume: 2,848,353
Technical Sentiment Signal: Buy
Current Market Cap: $16.23M
For a thorough assessment of QNTM stock, go to TipRanks’ Stock Analysis page.